Mutant p53-driven tumorigenesis
作者： Tamara Terzian , Guillermina Lozano
DOI: 10.1007/978-1-4614-3676-8_5
关键词:
摘要: Most tumors inactivate the p53 tumor suppressor pathway via single nucleotide changes of TP53 gene itself, which produces proteins with missense mutations. mutant clearly lose normal activities. Some are partial loss function mutations that retain some activities and probably cooperate other in to initiate development. Many mutants also exhibit gain-of-function dominant negative properties. Several mouse models have been generated these now offer opportunities study effects chemotherapeutic modalities.
springer.com
springerlink.com参考文章(101)
Goldfinger N, Rotter, Pinhasi-Kimhi O, Shaulsky G, Eliyahu D, Oren M, Arai N, Skurnik Y, Meth A fibrosarcoma cells express two transforming mutant p53 species. Oncogene. ,vol. 3, pp. 313- ,(1988)
D W Meek, Post-translational modification of p53. Seminars in Cancer Biology. ,vol. 5, pp. 203- 210 ,(1994)
S. Rowan, R. L. Ludwig, Y. Haupt, S. Bates, X. Lu, M. Oren, K. H. Vousden, Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant. The EMBO Journal. ,vol. 15, pp. 827- 838 ,(1996) , 10.1002/J.1460-2075.1996.TB00418.X
Charlotte Kuperwasser, Gregory D. Hurlbut, Frances S. Kittrell, Ellen S. Dickinson, Rudy Laucirica, Daniel Medina, Stephen P. Naber, D. Joseph Jerry, Development of spontaneous mammary tumors in BALB/c p53 heterozygous mice. A model for Li-Fraumeni syndrome. American Journal of Pathology. ,vol. 157, pp. 2151- 2159 ,(2000) , 10.1016/S0002-9440(10)64853-5
A. Shvarts, W. T. Steegenga, N. Riteco, T. van Laar, P. Dekker, M. Bazuine, R. C. van Ham, W. van der Houven van Oordt, G. Hateboer, A. J. van der Eb, A. G. Jochemsen, MDMX: a novel p53-binding protein with some functional properties of MDM2. The EMBO Journal. ,vol. 15, pp. 5349- 5357 ,(1996) , 10.1002/J.1460-2075.1996.TB00919.X
M. F. Santibanez-Koref, K. J. Tricker, D. G. R. Evans, J. M. Varley, J. M. Birch, A. M. Kelsey, M. Thorncroft, G. Mcgown, Germ-Line Mutations of TP53 in Li-Fraumeni Families: An Extended Study of 39 Families Cancer Research. ,vol. 57, pp. 3245- 3252 ,(1997)
Pierre Hainaut, Monica Hollstein, p53 and Human Cancer: The First Ten Thousand Mutations Advances in Cancer Research. ,vol. 77, pp. 81- 137 ,(1999) , 10.1016/S0065-230X(08)60785-X
Bert Vogelstein, David Lane, Arnold J. Levine, Surfing the p53 network Nature. ,vol. 408, pp. 307- 310 ,(2000) , 10.1038/35042675
P. J. Slootweg, M. G. C. T. Van Oijen, Gain-of-Function Mutations in the Tumor Suppressor Gene p53 Clinical Cancer Research. ,vol. 6, pp. 2138- 2145 ,(2000)
Ettore Appella, Carl W. Anderson, Post-translational modifications and activation of p53 by genotoxic stresses. FEBS Journal. ,vol. 268, pp. 2764- 2772 ,(2001) , 10.1046/J.1432-1327.2001.02225.X